ANAVEX LIFE SCIENCES CORP.(AVXL)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,858 of 3,068 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
AVXL Stock Analysis & AI Quality Score
Data updated 2026-08-29AI stock analysis and institutional research for ANAVEX LIFE SCIENCES CORP. (AVXL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AVXL at 24.6/100 on a 32-signal composite quality model, placing it at rank #2,858 of 3,068 stocks — the bottom half of the AI-ranked universe. Areas of concern include earnings quality (1.2) and institutional flow (7.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 30.0/100, reflecting ongoing share issuance or stock-based compensation. Top institutional holders of AVXL by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, TWO SIGMA INVESTMENTS, based on the most recent SEC filings. AVXL trades on the Nasdaq exchange and files with the SEC under CIK 1314052. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AVXL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ANAVEX LIFE SCIENCES CORP. directly from SEC EDGAR.
Net Income
Q2 2026
$7.8M
ROIC
Q2 2026
24.0%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-7.8% YoYOperating Income
+2.8% YoYEPS (Diluted)
-3.8% YoYTotal Assets
-23.4% YoYOp. Cash Flow
-26.7% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-46.4M -7.8% | $-43.0M +9.5% | $-47.5M +1.0% | $-48.0M -26.6% | $-37.9M -44.2% | $-26.3M |
| Operating Income | $-51.4M +2.8% | $-52.9M +5.2% | $-55.8M -9.4% | $-51.0M -21.4% | $-42.0M -35.1% | $-31.1M |
| EPS (Diluted) | $-0.54 -3.8% | $-0.52 +13.3% | $-0.60 +3.2% | $-0.62 -14.8% | $-0.54 | — |
| Total Assets | $103.8M -23.4% | $135.6M -12.2% | $154.4M +1.1% | $152.7M -5.5% | $161.6M +367.9% | $34.5M |
| Operating Cash Flow | $-39.0M -26.7% | $-30.8M -10.9% | $-27.8M -14.6% | $-24.2M +20.2% | $-30.4M -42.7% | $-21.3M |
Get alerted when AVXL's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ANAVEX LIFE SCIENCES CORP. including:
Top Institutional Holders of AVXL
BlackRock, Inc.
$20.9M8,055,628 shVANGUARD CAPITAL MANAGEMENT LLC
$10.5M4,054,589 shTWO SIGMA INVESTMENTS, LP
$7.9M3,046,538 shGEODE CAPITAL MANAGEMENT, LLC
$6.2M2,407,473 shSTATE STREET CORP
$5.0M1,922,770 shFEDERATED HERMES, INC.
$2.8M1,071,809 shAQR CAPITAL MANAGEMENT LLC
$2.5M963,014 shVANGUARD PORTFOLIO MANAGEMENT LLC
$2.5M948,633 shSummit Financial, LLC
$2.4M909,430 shGOLDMAN SACHS GROUP INC
$2.3M890,634 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $20.9M | 8,055,628 |
| VANGUARD CAPITAL MANAGEMENT LLC | $10.5M | 4,054,589 |
| TWO SIGMA INVESTMENTS, LP | $7.9M | 3,046,538 |
| GEODE CAPITAL MANAGEMENT, LLC | $6.2M | 2,407,473 |
| STATE STREET CORP | $5.0M | 1,922,770 |
| FEDERATED HERMES, INC. | $2.8M | 1,071,809 |
| AQR CAPITAL MANAGEMENT LLC | $2.5M | 963,014 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2.5M | 948,633 |
| Summit Financial, LLC | $2.4M | 909,430 |
| GOLDMAN SACHS GROUP INC | $2.3M | 890,634 |
Companies Similar to AVXL
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Alchemy Investments Acquisition Corp 1
BIOMERICA INC
American Outdoor Brands, Inc.
bioAffinity Technologies, Inc.
Ocean Power Technologies, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put AVXL on your watchlist
Track score changes the day ANAVEX LIFE SCIENCES CORP. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AVXL a good stock to buy?
13F Pro's AI-powered analysis of ANAVEX LIFE SCIENCES CORP. (AVXL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AVXL are available on the AVXL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. AVXL is classified as a small company.
Which hedge funds own AVXL?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AVXL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ANAVEX LIFE SCIENCES CORP.'s investment landscape.